Company news

Neuronetics, Inc. (NASDAQ:STIM) news

Every Neuronetics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Neuronetics, Inc. stock analysis →

Press releases & updates

NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System

September 8, 2026

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

August 11, 2026

Neuronetics and Jorey Chernett Announce Shared Vision

August 3, 2026

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

July 28, 2026

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

July 28, 2026

Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

July 20, 2026

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

July 6, 2026

Neuronetics Appoints Robert Greene as Senior Vice President Sales

June 2, 2026

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

June 2, 2026

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

May 14, 2026

Neuronetics Reports First Quarter 2026 Financial and Operating Results

May 5, 2026

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

April 21, 2026

Neuronetics Comments on Letter from Pointillist Family Office

April 7, 2026

Neuronetics Announces Chief Financial Officer Transition

April 6, 2026

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

March 17, 2026

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

March 17, 2026

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

March 3, 2026

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

February 10, 2026

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

November 20, 2025

TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression

November 12, 2025

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan

November 4, 2025

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 31, 2025

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excell...

October 30, 2025

Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call

October 21, 2025

New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

September 17, 2025

Neuronetics Reports Second Quarter 2025 Financial and Operating Results

August 5, 2025

Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

August 4, 2025

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents

July 30, 2025

Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call

July 22, 2025

Neuronetics Appoints New Chief Financial Officer

July 15, 2025

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Tr...

June 10, 2025

Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

June 2, 2025

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

May 14, 2025

Neuronetics Reports First Quarter 2025 Financial and Operating Results

May 6, 2025

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

April 22, 2025

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

March 31, 2025

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

March 27, 2025

Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

March 4, 2025

Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

February 21, 2025

Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

February 7, 2025

Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

February 6, 2025

NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression

January 29, 2025

Neuronetics Provides Business Update and Issues 2025 Guidance

January 13, 2025

Neuronetics and Greenbrook TMS Announce Closing of Transaction

December 10, 2024

Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference

November 20, 2024

Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

November 12, 2024

Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

October 29, 2024

NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression

October 14, 2024

Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Me...

October 4, 2024

Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults

September 19, 2024

Older →